2023 Fall Clinical Virtual Grand Rounds

2023 Virtual Grand Rounds Session 1: February 1, 2023 - WCH23 Your Questions Answered

About

Fall Clinical Virtual Grand Rounds consists of regularly scheduled CME sessions on a variety of dermatological diseases and tools, delivered by the top experts in dermatology.

Please join us for this week's session:
Wednesday, February 1, 2023 
8 PM ET/ 5 PM PT

Winter Clinical Dermatology Conference-Hawaii 2023 (WCH23) Recap: Your Questions Answered

Availability

In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:

Release Date:

February 1, 2023

Expiration Date:

February 1, 2024

Learning Objectives

At the completion of this activity, participants should be better able to:

  • Illustrate strategies to manage dermatologic conditions effectively in clinical practice

  • Discuss the treatment of psoriasis and related disorders with evolving therapies

  • Describe the modalities for diagnosing and managing skin cancer

  • Describe strategies to prepare and administer fillers and botulinum

Intended Audience
This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.
Faculty
April
April Armstrong, MD, MPH

Chief, Division of Dermatology
David Geffen School of Medicine at UCLA
Los Angeles, CA

James
James Del Rosso, DO

Adjunct Clinical Professor, Dermatology
Touro University Nevada
Henderson, NV

Seemal
Seemal Desai, MD

Clinical Assistant Professor
Department of Dermatology
University of Texas Southwestern Medical Center
Dallas, TX

Gary
Gary Goldenberg, MD

Assistant Clinical Professor of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY

Mark
Mark Lebwohl, MD

Dean for Clinical Therapeutics
Waldman Professor
Chairman Emeritus
Kimberly and Eric J. Waldman Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY

Darrell
Darrell Rigel, MD, MS

Clinical Professor of Dermatology 
Director, Melanoma Surveillance Clinic 
Mount Sinai Icahn School of Medicine, New York, NY 
Adjunct Professor, UT Southwestern Medical School 
Consultant Dermatologist, Cooper Clinic, Dallas, TX

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Institute for Continuing Healthcare Education and CMEsquared. The Institute is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The Institute for Continuing Healthcare Education designates this live and enduring activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures & Disclaimers

CONFLICTS OF INTEREST/DISCLOSURES

In accordance with the ACCME Standards for Commercial Support, balance, independence, objectivity, and scientific rigor are ensured in all CME activities. This requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with any ineligible companies. In addition, the content of this material has been approved by an independent peer reviewer. 

Disclosures are as follows:

April W. Armstrong, MD, MPH

Grant/Research Support: BMS, Leo, UCB, Lilly, Dermavant, Dermira, Pfizer, AbbVie, ASLAN, BI, EPI, Incyte, Janssen 

Consultant: Lilly, Novartis, Ortho, SUN, Dermavant, Dermira, Sanofi Regeneron, Pfizer, Parexel 

James Q. Del Rosso, DO

Grant/Research Support: Aclaris, Amgen, Anaptys Bio, Arcutis, Athenex, Bausch (Ortho), Biorasi, Botanix, Brickell, Cara Therapeutics, Cassiopea, Dermavant, EPI Health, Galderma, Genentech, Incyte, Janssen, LEO, Lilly, Novan, Pfizer, Ralexar, Sanofi Genzyme Regeneron, Sol-Gel, SUN, Vyne

Consultant: Abbvie, Aclaris, Almirall, Amgen, Arcuits, Bausch (Ortho), Biofrontera, Biopharmx, Blue Creek, BMS, Cassiopea, Dermata, Dermavant, Encore, EPI Health, Evoummune, Ferndale, Galderma, Incyte, Jem Health, LEO, La Roche Posay, Lilly, MC2, Novan, Pfizer, Sanofi Genzyme Regeneron, Sente, Sol-Gel, Sonoma, SUN, UCB, Verrica, Vyne

Speakers’ Bureau or Honoraria: Abbvie, Aclaris, Almiral, Amgen, Bausch (Ortho), Biofrontera, Encore, EPI Health Ferndale, Galderma, Genentech, Jem Health, LEO, Lilly, Pfizer, Sanofi Genzyme Regeneron, SUN, UCB, Verrica, Vyne

Seemal R. Desai, MD

Grant/Research Support: AbbVie, Incyte, Dermavant, AOBiome,

Consultant: Galderma, Almirall, Ferndale, BMS, AbbVie, Verrica, UCB, Ortho, Scientis, EPI, Avita, Eli Lilly, Leo, Pfizer, Incyte, L’Oreal, Beiersdorf, J&J

Speakers’ Bureau or Honoraria: Dermavant, Galderma, Pfizer

Gary Goldenberg, MD

Grant/Research Support: Biofrontera 
Consultant: CoolHealth, Cutera, Galderma, Regeneron, Sanofi, Scibase 
Speakers’ Bureau or Honoraria: Regeneron Sanofi 
Ownership Interest: Verrica

Mark Lebwohl, MD

Grant/Research Support: Abbvie, Amgen, Arcutis, Avotres, Boehringer Ingelheim, Cara Therapeutics, Dermavant Sciences, Eli Lilly, Incyte, Inozyme, Janssen Research & Development, LLC, Novartis, Ortho Dermatologics, Regeneron, and UCB, Inc.

Consultant: AnaptysBio, Arcutis, Inc., Arena Pharmaceuticals, Aristea Therapeutics, Avotres Therapeutics, BioMX, Boehringer-Ingelheim, Brickell Biotech, Cara Therapeutics, Castle Biosciences, Corevitas, Dermavant Sciences, Evommune, Inc., Facilitation of International Dermatology Education, Hexima Ltd., Meiji Seika Pharma, Mindera, National Society of Cutaneous Medicine, New York College of Podiatric Medicine, Pfizer, Seanergy, SUN Pharma, Verrica, and Vial.

Darrell S. Rigel, MD, MS

Grant/Research Support: Castle Biosciences, SciBASE

Consultant: DermTech, Ferndale Laboratories, Inc., SciBase, VYNE Therapeutics 

Speakers’ Bureau or Honoraria: Castle Biosciences

Advisory Board: Almirall, Beiersdorf, Inc., Castle Biosciences, Johnson and Johnson 

The planners have disclosed that they have no relevant financial relationships with any Ineligible Company in the past 24 months.  

The Institute discloses that all relevant conflicts have been satisfactorily mitigated.


Dermsquared

The leading platform for dermatology professionals to elevate patient care.

Contact Us

Support

Subscribe now

Enter your email to get the latest updates.

© 2023 dermsquared | All Rights Reserved